Table 2.
Univariate and multivariate analysis of clinical and pathologicalal response rates by biological factors
| Factors | Univariate analysis | Multivariate analysis | ||||
|---|---|---|---|---|---|---|
| OR | 95%CI | P-value | OR | 95%CI | P-value | |
| age (years) | ||||||
| ≤ 45 | Ref | |||||
| > 45 | 0.792 | 0.394–1.593 | 0.513 | |||
| BMI (kg/m2) | ||||||
| < 25 | Ref | |||||
| ≥ 25 | 1.384 | 0.617–3.102 | 0.430 | |||
| Menopausal status | ||||||
| Postmenopausal | Ref | |||||
| Premenopausal | 1.130 | 0.569–2.245 | 0.726 | |||
| Multifocality | ||||||
| Multifocal | Ref | |||||
| Unifocal | 0.821 | 0.353–1.911 | 0.648 | |||
| Local invasion | ||||||
| Yes | Ref | |||||
| No | 0.432 | 0.051–3.690 | 0.443 | |||
| LVI | ||||||
| Absent | Ref | |||||
| Present | 0.292 | 0.106–0.800 | 0.017 | 0.314 | 0.108–0.918 | 0.034 |
| Clinical tumor size | ||||||
| T1 | Ref | |||||
| T2 | 0.762 | 0.267–2.173 | 0.533 | |||
| T3 | 0.948 | 0.255–3.525 | 0.875 | |||
| Lymph node status | ||||||
| N0 | Ref | |||||
| N1–2 | 1.185 | 0.560–2.507 | 0.657 | |||
| Histological grade | ||||||
| I-II | Ref | |||||
| III | 1.427 | 0.667–3.054 | 0.360 | |||
| Histologic type | ||||||
| IDC | Ref. | . | ||||
| Others | 4.889 | 0.617–38.739 | 0.133 | |||
| Progesterone receptor | ||||||
| Negative | Ref. | . | ||||
| Positive | 0.451 | 0.222–0.917 | 0.028 | |||
| Estrogen receptor | ||||||
| Negative | Ref | Ref | ||||
| Positive | 0.286 | 0.118–0.694 | 0.006 | 0.342 | 0.132–0.889 | 0.028 |
| Hormone receptor | ||||||
| Negative | Ref | |||||
| Positive | 0.497 | 0.246–1.002 | 0.051 | |||
| HER2 | ||||||
| Negative | Ref | |||||
| Positive | 1.833 | 0.914–3.678 | 0.088 | |||
| Ki67 | ||||||
| ≤ 60% | Ref. | . | Ref | |||
| > 60% | 0.363 | 0.175–0.751 | 0.006 | 0.258 | 0.106–0.627 | 0.003 |
| Molecular subtype | ||||||
| Luminal B | Ref. | . | ||||
| HER2 enriched | 0.072 | 0.016–0.324 | 0.001 | |||
| Triple negative | 0.711 | 0.331–1.527 | 0.046 | |||
| NCT regimen | ||||||
| TEC | Ref | Ref | ||||
| TCbH | 2.228 | 1.103–4.501 | 0.025 | 3.268 | 1.380–7.738 | 0.007 |
| NCT time, cycles | ||||||
| ≤ 4 | Ref. | . | ||||
| > 4 | 0.390 | 0.127–1.196 | 0.100 | |||
| Hemoglobin(g/L) | ||||||
| ≤ 120 | Ref | |||||
| > 120 | 0.359 | 0.140–0.923 | 0.033 | 0.423 | 0.154–0.988 | 0.046 |
Abbreviations: OR odds ratio, CI confidence interval, BMI body mass index, pCR pathologic complete response, NCT Neoadjuvant chemotherapy, IDC Invasive ductal carcinoma, HER2 Human epidermal growth factor receptor, LVI lymphovascular invasion, Others: invasive lobular carcinoma, metaplastic carcinoma and medullary carcinoma